Docetaxel/vinorelbine combination therapy in non-small-cell lung cancer
Docetaxel (Taxotere) has demonstrated significant activity as a single agent in the treatment of patients with advanced non-small-cell lung cancer. Projected median survival in both previously untreated and treated patients is reported to be 9 months. In addition, response rates have ranged from 33% to 38% and 21% to 27% in these respective patient populations. Because vinorelbine (Navelbine) has been demonstrated to have a survival benefit in randomized trials in patients with non-small-cell lung cancer, the potential for the combined use of these agents is promising. In addition, the side effect profiles of docetaxel and vinorelbine are compatible for the combined use of these agents in patients with advanced non-small-cell lung cancer. Preliminary results from phase I and II combination studies have shown encouraging results, with partial responses ranging from 23% to 55%. Based on these data, further study into the combined use of docetaxel and vinorelbine in patients with non-small-cell lung cancer is warranted.
